FundaMental Pharma GmbH, a Heidelberg, Germany-based preclinical neuroscience company, raised €10M in Seed funding.
The round was led by BioGeneration Ventures and Thuja Capital, with participation from High Tech Gründerfonds.
The company intends to use the funds to accelerate growth, and expand its development efforts.
Built on the pioneering research of Professor Hilmar Bading and Dr. Jing Yan and founded by Dr. Thomas Schulze, and Professor Hilmar Bading, FundaMental Pharma is a neuroscience company, spun out of Heidelberg University, developing small inhibitors for treatment of a range of neurodegenerative diseases. Its scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. While FundaMental current focus is on Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease, the applicability of these molecules extend to a range of neurogenerative disorders such as dementia and aging-related memory loss.
In conjunction with the financing, FundaMental also announced several key senior management appointments as well as the Board of Directors of the company. Dr. Gabriele Hecker-Barth has joined as Chief Medical Officer and Dr. Jing Yan as Senior Director of Research. Dr. Keno Gutierrez of BGV and Dr. Michel Briejer of Thuja Capital, Professor Hilmar Bading and Dr. Thomas Schulze have been appointed to the company’s Board of Directors.
FinSMEs
21/11/2022